ATNM (Actinium Pharmaceuticals) GF Score : 27/100 (As of Dec. 12, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Actinium Pharmaceuticals GF Score?

Actinium Pharmaceuticals has the GF Score of 27, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Actinium Pharmaceuticals might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Actinium Pharmaceuticals's GF Score

For the Biotechnology subindustry, Actinium Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actinium Pharmaceuticals's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's GF Score distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's GF Score falls into.

Actinium Pharmaceuticals (AMEX:ATNM) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Actinium Pharmaceuticals GF Score Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinium Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (AMEX:ATNM) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

7AY1:Germany

Address

100 Park Avenue, 23rd Floor, New York, NY, USA, 10017

Website

https://www.actiniumpharma.com

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Executives

Sandesh Seth	director	300 E 93RD STREET, #20-B, NEW YORK NY 10128
Steve O'loughlin	officer: VP, Finance and Corporate Dev.	955 HARTMAN RUN ROAD, MORGANTOWN WV 26507
Dale L. Ludwig	officer: Chief Scientific Officer	21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028
Jeffrey W. Chell	director	521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767
Ajit Shetty	director	643 ZEEDIJK, KNOKKE C9 8300
Anil Kapur	officer: Chief Commercial Officer	275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Nitya G. Ray	officer: Executive Vice President	14 BAYBURY COURT, EAST HANOVER NJ 07936
Mark Stanley Berger	officer: Chief Medical Officer	140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Memorial Sloan-kettering Cancer Center	10 percent owner	1275 YORK AVE., NEW YORK NY 10065
Sergio Traversa	director	138 CANTERBURY LN, BLUE BELL PA 19422
C. David Nicholson,	director	103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Kaushik J Dave	director, officer: President and CEO	4 WATER STREET, EDISON NJ 08820
Richard I Steinhart	director	125 ELM STREET, NEW CANAAN CT 06840
Ahlb Holdings, Llc	10 percent owner	C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065
Actinium Holdings, Ltd.	10 percent owner	C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000